# ConvaTec Group reports accelerating organic revenue growth of 7.2%

- Link: https://www.directorstalkinterviews.com/convatec-group-reports-accelerating-organic-revenue-growth-of-7.2/4121146393
- Published: 2024-03-06T07:46:44+00:00
- Author: Amilia Stone

**ConvaTec Group plc** (LON:CTEC) has announced its Annual Results for the twelve
months ended 31 December 2023.

**Accelerating organic revenue growth of 7.2%****^(1)****, broad-based across all
four chronic care categories**

·    AWC^(2): 9.5%^(1) driven by strong performance in antimicrobials and growing
position in wound biologics segment^(3)

·    OC^(2): 4.2%^(1) driven by 6% growth in Convatec ostomy products with strength
in Global Emerging Markets

·    CC^(2): 6.5%^(1) excellent customer service and higher reimbursement pricing
in the US

·    IC^(2): 8.7%^(1) continued strong demand for infusion sets with multiple product
launches in 2023

Reported revenue was $2,142m (2022: $2,073m), up 3.4% and 3.2% on a constant currency
^(4) basis, lower than organic because of the strategic exit of the non-core hospital
care activities and related industrial sales in 2022

**Further operating margin expansion**

·    Strong adjusted gross margin expansion of 150bps to 61.6% principally driven
by improved mix and stronger pricing coupled with further productivity, partially
offset by inflation and FX

·    Adjusted operating profit margin of 20.2% (20.8% on a constant currency basis).
Expansion of 70 bps (130 bps on a constant currency basis) with further progress
in simplification and productivity of operating costs

·    Adjusted operating profit up 7.0% to $432m.  Reported operating profit increased
to $263m (2022: $207m)

**Delivering EPS and cashflow growth**

·    Adjusted diluted EPS increased 6.1% to 13.4 cents.  Reported diluted EPS increased
106% to 6.3 cents

·    Free cash flow to equity^(5) rose to $228m (2022: $105m) resulting in equity
cash conversion^(5) of 83%

**Strong new product pipeline – further strengthening competitive position

·    Growing InnovaMatrix^(®) and ConvaFoam^(TM) in the US – positive clinician 
feedback

·    Acquired innovative anti-infective nitric oxide technology platform

·    Launching new compact hydrophilic catheter, GentleCath^(TM) Air for Women, 
in Europe

·    Broadening customers and applications in IC – partnerships with Beta Bionics(
iLet insulin pump in the US), AbbVie and Mitsubishi Tanabe (Parkinson’s), Medtronic(
780G in the US) and Tandem (Mobi in the US)

**Confidence in outlook – improving earnings and cash generation**

·    In 2024: we expect 5-7% organic revenue growth, adjusted operating profit margin
of at least 21.0% on a constant currency basis and double-digit growth in EPS and
free cash flow to equity

·    Medium-term: Based on the strength of the new product pipeline and improvements
in commercial execution we have raised our organic revenue growth expectation to
5-7% p.a. (previously 4-6%), we also expect to reach a mid 20’s% adjusted operating
profit margin by 2026 or 2027 and to deliver double-digit compound annual growth
in EPS and free cash flow to equity

> **Karim Bitar, Chief Executive Officer, commented:**
> “Convatec’s revenue growth accelerated and was broad-based across all our categories.
> We further expanded our operating margin and increased earnings per share and 
> free cash flow to equity.
> “We remain focused on executing our FISBE 2.0 strategy. Given our innovative new
> product pipeline and strengthened competitive position, Convatec has pivoted to
> a higher level of organic sales growth. We are on track to deliver our medium-
> term margin guidance leading to double-digit compound growth in EPS and free cash
> flow to equity.”

**Key financial highlights**

|  | **Reported** | **Adjusted** | 
|  | **FY 2023** | **FY 2022** | **Change** | **FY 2023** | **FY 2022** | **Change** | **CC Change** | 
| Revenue | $2,142m | $2,073m | 3.4% | $2,142m | $2,073m | 3.4% | 3.2% | 
| Operating profit | $263m | $207m | 26.7% | $432m | $404m | 7.0% | 10.2% | 
| Operating profit margin | 12.3% | 10.0% | 2.3%pts | 20.2% | 19.5% | 0.7%pts | 1.3%pts | 
| Diluted EPS | 6.3 cents | 3.1 cents | 105.9% | 13.4 cents | 12.6 cents | 6.1% |  | 
| Dividend per share | 6.229 | 6.047 | 3.0% |  |  |  |  |

·    Net debt^(4) increased by $61m to $1,129m. Net debt to EBITDA ratio was maintained
at 2.1x after $179m of M&A investment and $129m in capex investment to drive future
growth, coupled with $111m dividend payment

·    The Board recommends a final dividend of 4.460 cents resulting in full year
dividend of 6.229 cents, an increase of 3%

_Percentage movements throughout this release are calculated on actual unrounded
numbers._

_(1) Organic growth presents period over period growth at constant currency, adjusted
for: Triad Life Sciences acquisition (Mar’22) the exit of hospital care and related
industrial sales and the reconfigured business in Russia (May’22) and the acquisition
of A Better Choice Medical (Jul’23)_

_(2) AWC is Advanced Wound Care; OC is Ostomy Care; CC is Continence Care and IC
is Infusion Care_

_(3) Wound Biologics segment, as defined by SmartTRAK.  This segment includes skin
substitutes, active collagen dressings and topical drug delivery.  Triad Life Sciences
was renamed Advanced Tissue Technologies (ATT) following its acquisition in mid-
March 2022.  ATT began to contribute to the organic growth rate following the anniversary
of the deal completion. _

_(4) Constant currency growth is calculated by applying the applicable prior period
average exchange rates to the Group’s actual performance in the respective period._

_(5) Certain financial measures in this document, including adjusted results above,
are not prepared in accordance with International Financial Reporting Standards (
IFRS). All adjusted measures are reconciled to the most directly comparable measure
prepared in accordance with IFRS in the Non-IFRS Financial Information below (pages
21 to 26).   Equity cash conversion is a new non-IFRS financial measure introduced
in the year and is calculated as Free cash to equity/Adjusted net profit._

**Investor and analyst presentation**

The results presentation will be held in person at The Auditorium, Chartered Accountants’
Hall, One Moorgate Place, London EC2R 6EA at 9.00am (UK time) today. The event will
be simultaneously webcast and the link can be found [here](https://stream.brrmedia.co.uk/broadcast/65c368753fb3f51bf67d309c).

The full text of this announcement and the presentation for the analyst and investors
meeting can be found on the ‘Results, Reports & Presentations’ page of the Convatec
website www.convatecgroup.com/investors/reports.

**Forthcoming events**

| Trading update for the 4 months ending 30 April 2024: | 16 May 2024 | 
| Interim results: | 30 July 2024 |

**Dividend calendar**

| Ex Dividend | 25 April 2024 | 
| Record Date | 26 April 2024 | 
| AGM | 16 May 2024 | 
| Payment date | 23 May 2024 |

Share on:
